Less than a tenth of patients eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it publishes its initial recommendations on the medications.
With more than one billion people worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.
Per projections, over two billion will be obese by 2030 if no action is taken.
"The new guidance affirms that obesity is a chronic disease that can be treated with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major obstacles to widespread access to the treatments that can assist patients in reducing significant body mass, says the agency.
Skinny Jab Shortage
Even under the present most favorable outlook, the manufacturing of these medications might only reach around 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation encourages governments and firms to widen availability, via measures like voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Injections Work
These medications mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so people eat less.
Patients commonly begin shedding pounds in the initial weeks of starting on the regular doses.
Research points to users may regain a significant portion after a year of halting the medication, because their typical appetite come back.
To be overweight or obese elevates your risk for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns people in all nations and was linked to millions of deaths worldwide in 2024, as per the health agency.
